Luminal Flow Amplifies Stent-Based Drug Deposition in Arterial Bifurcations

Background Treatment of arterial bifurcation lesions using drug-eluting stents (DES) is now common clinical practice and yet the mechanisms governing drug distribution in these complex morphologies are incompletely understood. It is still not evident how to efficiently determine the efficacy of local drug delivery and quantify zones of excessive drug that are harbingers of vascular toxicity and thrombosis, and areas of depletion that are associated with tissue overgrowth and luminal re-narrowing. Methods and Results We constructed two-phase computational models of stent-deployed arterial bifurcations simulating blood flow and drug transport to investigate the factors modulating drug distribution when the main-branch (MB) was treated using a DES. Simulations predicted extensive flow-mediated drug delivery in bifurcated vascular beds where the drug distribution patterns are heterogeneous and sensitive to relative stent position and luminal flow. A single DES in the MB coupled with large retrograde luminal flow on the lateral wall of the side-branch (SB) can provide drug deposition on the SB lumen-wall interface, except when the MB stent is downstream of the SB flow divider. In an even more dramatic fashion, the presence of the SB affects drug distribution in the stented MB. Here fluid mechanic effects play an even greater role than in the SB especially when the DES is across and downstream to the flow divider and in a manner dependent upon the Reynolds number. Conclusions The flow effects on drug deposition and subsequent uptake from endovascular DES are amplified in bifurcation lesions. When only one branch is stented, a complex interplay occurs – drug deposition in the stented MB is altered by the flow divider imposed by the SB and in the SB by the presence of a DES in the MB. The use of DES in arterial bifurcations requires a complex calculus that balances vascular and stent geometry as well as luminal flow.

[1]  S Chien,et al.  Effects of hematocrit and plasma proteins on human blood rheology at low shear rates. , 1966, Journal of applied physiology.

[2]  Patrick W. Serruys,et al.  Handbook of Coronary Stents , 1997 .

[3]  E. Edelman,et al.  Arterial paclitaxel distribution and deposition. , 2000, Circulation research.

[4]  E. Edelman,et al.  Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. , 2001, Journal of pharmaceutical sciences.

[5]  J J Wentzel,et al.  Relationship Between Neointimal Thickness and Shear Stress After Wallstent Implantation in Human Coronary Arteries , 2001, Circulation.

[6]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[7]  Prototype stents set to steal market , 2002, Nature Medicine.

[8]  Pedro A. Lemos,et al.  Drug‐Eluting Stents: Cost Versus Clinical Benefit , 2003, Circulation.

[9]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[10]  Muzaffer Degertekin,et al.  TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation , 2003, Circulation.

[11]  E. Edelman,et al.  Impact of transport and drug properties on the local pharmacology of drug-eluting stents , 2003, International journal of cardiovascular interventions.

[12]  H. Meng,et al.  Effects of arterial geometry on aneurysm growth: three-dimensional computational fluid dynamics study. , 2004, Journal of neurosurgery.

[13]  E. Edelman,et al.  Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. , 2004, The Journal of clinical investigation.

[14]  P. Serruys,et al.  Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II Trial , 2004, Circulation.

[15]  J. Tarbell,et al.  Fenestral Pore Size in the Internal Elastic Lamina Affects Transmural Flow Distribution in the Artery Wall , 2001, Annals of Biomedical Engineering.

[16]  Antonio Colombo,et al.  Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions , 2004, Circulation.

[17]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[18]  A. Tzafriri,et al.  Strut Position, Blood Flow, and Drug Deposition: Implications for Single and Overlapping Drug-Eluting Stents , 2005, Circulation.

[19]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[20]  E. Edelman,et al.  Cardiology is flow. , 2006, Circulation.

[21]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[22]  Elazer R Edelman,et al.  Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[23]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[24]  A. Colombo,et al.  Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease) , 2007, Circulation.

[25]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[26]  Neil W Bressloff,et al.  Mining data from hemodynamic simulations via Bayesian emulation , 2007, Biomedical engineering online.

[27]  A. Colombo,et al.  Bifurcation stenting: current strategies and new devices , 2008, Heart.

[28]  Elazer R Edelman,et al.  Thrombus causes fluctuations in arterial drug delivery from intravascular stents. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[29]  A. Tzafriri,et al.  Luminal flow patterns dictate arterial drug deposition in stent-based delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Early and long‐term results of percutaneous coronary intervention for unprotected left main trifurcation disease , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[31]  Imad Sheiban,et al.  Update on dedicated bifurcation stents. , 2009, Journal of interventional cardiology.